Data on the combination of darunavir/ritonavir and etravirine both given twice daily in adolescents/young adults are lacking. In this study, we assessed the pharmacokinetics of darunavir/ ritonavir 600/100 mg with etravirine 200 mg twice daily in 36 treatment-experienced human immunodeficiency virus-infected adolescents and young adults and found that exposures were comparable to those reported in adults.
|Original language||English (US)|
|Number of pages||3|
|Journal||Journal of the Pediatric Infectious Diseases Society|
|State||Published - Sep 1 2017|
ASJC Scopus subject areas